Literature DB >> 6607312

Identification of a specific interleukin 1 inhibitor in the urine of febrile patients.

Z Liao, R S Grimshaw, D L Rosenstreich.   

Abstract

The urine of febrile patients has been found to contain high concentrations of an inhibitor of interleukin 1 (IL-1)-induced thymocyte proliferation. The inhibitor is specific for IL-1 and does not block the effects of interleukin 2 (IL-2) or phytohemagglutin (PHA) on thymocytes, and it is not nonspecifically toxic for these cells. IL-1 inhibitor can be found in the urine of normal individuals and afebrile patients, but is present in increased concentrations in the urine of patients with fever of diverse etiologies. Preliminary physicochemical characterization indicates that the inhibitor is a 20-40-kdalton protein.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6607312      PMCID： PMC2187209          DOI： 10.1084/jem.159.1.126

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  21 in total

1.  Isolation and partial characterization of a low molecular weight trypsin inhibitor from human urine.

Authors:  G Fex; A Grubb; C Loeffler; J Larsson
Journal:  Biochim Biophys Acta       Date:  1981-02-27

2.  Phorbol myristate acetate and in vitro T lymphocyte function. I. PMA may contaminate lymphokine preparations and can interfere with interleukin bioassays.

Authors:  C G Orosz; D C Roopernian; F H Bach
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

3.  Macrophage-independent activation of helper T cells. I. Production of Interleukin 2.

Authors:  J J Farrar; S B Mizel; J Fuller-Farrar; W L Farrar; M L Hilfiker
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

4.  The role of macrophages in the acute-phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen.

Authors:  M B Sztein; S N Vogel; J D Sipe; P A Murphy; S B Mizel; J J Oppenheim; D L Rosenstreich
Journal:  Cell Immunol       Date:  1981-09-01       Impact factor: 4.868

5.  Suppression of lymphocyte responses by tuberculous plasma and mycobacterial arabinogalactan. Monocyte dependence and indomethacin reversibility.

Authors:  M E Kleinhenz; J J Ellner; P J Spagnuolo; T M Daniel
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

6.  The effects of electrophoretically "slow" and "fast" alpha-2 macroglobulin on mixed lymphocyte cultures.

Authors:  W J Hubbard; A D Hess; S Hsia; D B Amos
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

7.  Monokine-induced synthesis of serum amyloid A protein by hepatocytes.

Authors:  M J Selinger; K P McAdam; M M Kaplan; J D Sipe; S N Vogel; D L Rosenstreich
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

8.  Thymoma production of T cell growth factor (Interleukin 2).

Authors:  J J Farrar; J Fuller-Farrar; P L Simon; M L Hilfiker; B M Stadler; W L Farrar
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

9.  The role of alpha 1 protease inhibitor (alpha 1 antitrypsin) in the regulation of immunologic and inflammatory reactions.

Authors:  S N Breit; R Penny
Journal:  Aust N Z J Med       Date:  1980-08

10.  Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1).

Authors:  S B Mizel; J M Dayer; S M Krane; S E Mergenhagen
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205
View more
  51 in total

1.  IL-1 receptor accessory protein-Ig/IL-1 receptor type II-Ig heterodimer inhibits IL-1 response more strongly than other IL-1 blocking biopharmaceutical agents.

Authors:  Haruo Hanawa; Yoshimi Ota; Limin Ding; He Chang; Kaori Yoshida; Keita Otaki; Kazuhisa Hao; Sou Kasahara; Makoto Kodama; Mikio Nakazawa; Yoshifusa Aizawa
Journal:  J Clin Immunol       Date:  2010-12-22       Impact factor: 8.317

2.  Inhibitor of interleukin-1 alpha and interleukin-1 beta-induced T-cell activation in serum of patients with active Crohn's disease.

Authors:  J Brynskov; M B Hansen; C Reimert; K Bendtzen
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

3.  The effect of experimental haemocarbofiltration upon activity of mononuclear cells from normal and autoimmune patients.

Authors:  S A Grando; B T Glukhenky; G N Drannik; A P Kostromin; A B Romanenko
Journal:  Immunology       Date:  1989-01       Impact factor: 7.397

4.  Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies.

Authors:  M Lotz; C D Tsoukas; C A Robinson; C A Dinarello; D A Carson; J H Vaughan
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

5.  Modulation of gingival Langerhans cell T6 antigen expression in vitro by interleukin 1 and an interleukin 1 inhibitor.

Authors:  L J Walsh; G J Seymour; R N Powell
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

6.  A low molecular weight proteinase inhibitor produced by T lymphocytes.

Authors:  D Ganea; M Teodorescu; S Dray
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

7.  Release of interleukin 1 inhibitory activity (contra-IL-1) by human monocyte-derived macrophages infected with human immunodeficiency virus in vitro and in vivo.

Authors:  R M Locksley; S Crowe; M D Sadick; F P Heinzel; K D Gardner; M S McGrath; J Mills
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

8.  Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide.

Authors:  T Nishihara; T Koga; S Hamada
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

9.  Uromodulin, an immunosuppressive protein derived from pregnancy urine, is an inhibitor of interleukin 1.

Authors:  K M Brown; A V Muchmore; D L Rosenstreich
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

10.  An interleukin-1 inhibitor in gingival crevicular fluid of patients with chronic inflammatory periodontal disease.

Authors:  H Kabashima; K Maeda; H Iribe; K Yamashita; T Hirofuji; Y Iwamoto; M Aono
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.